Study Protocol: A Pilot Study to Determine the Safety and Efficacy of Induction-Therapy, de Novo MPA and Delayed mTOR-Inhibition in Liver Transplant Recipients with Impaired Renal Function. PATRON-Study

BMC Nephrology

Volumn 11, Issue 1, 2010, Pages

  Schnitzbauer, Andreas A ^a   Scherer, Marcus N ^a   Rochon, Justine ^a   Sothmann, Johannes ^a   Farkas, Stefan A ^a   Loss, Martin ^a   Geissler, Edward K ^a   Obed, Aiman ^a   Schlitt, Hans J ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CREATININE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; STEROID; DRUG DERIVATIVE; HYBRID PROTEIN; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID;

ARTICLE; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DYSFUNCTION; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LOADING DRUG DOSE; PROSPECTIVE STUDY; STEROID THERAPY; SURVIVAL; TREATMENT OUTCOME; TREATMENT PLANNING; DRUG COMBINATION; GRAFT REJECTION; KIDNEY FAILURE; METHODOLOGY; PATHOPHYSIOLOGY; PATIENT SELECTION; PILOT STUDY;

ANTIBODIES, MONOCLONAL; DRUG THERAPY, COMBINATION; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MYCOPHENOLIC ACID; PATIENT SELECTION; PILOT PROJECTS; RECOMBINANT FUSION PROTEINS; RENAL INSUFFICIENCY; RESEARCH DESIGN; SIROLIMUS; STEROIDS; TREATMENT OUTCOME;

EID: 77957306398     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-11-24     Document Type: Article

References (19)

1. Post-liver transplant acute renal failure: factors predicting development of end-stage renal disease. AS Paramesh S Roayaie Y Doan, et al. Clin Transplant 2004 18 94 99 10.1046/j.1399-0012.2003.00132.x 15108777
2. Renal outcomes after liver transplantation in the model for end-stage liver disease era. P Sharma K Welch R Eikstadt JA Marrero RJ Fontana AS Lok, Liver Transpl 2009 15 1142 1148 10.1002/lt.21821 19718633
3. Renal function after orthotopic liver transplantation is predicted by duration of pretransplantation creatinine elevation. MS Campbell DS Kotlyar CM Brensinger, et al. Liver Transpl 2005 11 1048 1055 10.1002/lt.20445 16123966
4. Risk factors of acute renal failure after liver transplantation. JB Cabezuelo P Ramirez A Rios, et al. Kidney Int 2006 69 1073 1080 10.1038/sj.ki.5000216 16528257
5. Impact of acute renal failure on mortality in end-stage liver disease with or without transplantation. DS Fraley R Burr J Bernardini D Angus DJ Kramer JP Johnson, Kidney Int 1998 54 518 524 10.1046/j.1523-1755.1998.00004.x 9690218
6. Evaluation of acute renal failure in the liver transplantation perioperative period: incidence and impact. FJ Gainza A Valdivieso N Quintanilla, et al. Transplant Proc 2002 34 250 251 10.1016/S0041-1345(01)02747- 6 11959269
7. End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment. TA Gonwa ML Mai LB Melton, et al. Transplantation 2001 72 1934 1939 10.1097/00007890-200112270-00012 11773892
8. Risk factors for renal dysfunction in the postoperative course of liver transplant. GM Lebron ME Herrera Gutierrez PG Seller BE Curiel JF Fernandez Ortega GG Quesada, Liver Transpl 2004 10 1379 1385 10.1002/lt.20215 15497160
9. Chronic renal failure after transplantation of a nonrenal organ. AO Ojo PJ Held FK Port, et al. N Engl J Med 2003 349 931 940 10.1056/NEJMoa021744 12954741
10. Posttransplantation dialysis-associated infections: morbidity and impact on outcome in liver transplant recipients. N Singh T Gayowski MM Wagener, Liver Transpl 2001 7 100 105 10.1053/jlts.2001.21304 11172392
11. Risk factors for postoperative acute renal failure at a new orthotopic liver transplantation program. MR vares-da-Silva FL Waechter CF Francisconi, et al. Transplant Proc 1999 31 3050 3052 10.1016/S0041-1345(99)00666-1 10578389
12. Independent risk factors and natural history of renal dysfunction in liver transplant recipients. A Pawarode DM Fine PJ Thuluvath, Liver Transpl 2003 9 741 747 10.1053/jlts.2003.50113 12827563
13. Update and actual trends on bacterial infections following liver transplantation. JL del Pozo, World J Gastroenterol 2008 14 4977 4983 10.3748/wjg.14.4977 18763277
14. Causes of death in autopsied liver transplantation patients. M Torbenson J Wang L Nichols A Jain J Fung MA Nalesnik, Mod Pathol 1998 11 37 46 9556421 (Pubitemid 28177362)
15. Infections after liver transplantation. An analysis of 101 consecutive cases. S Kusne JS Dummer N Singh, et al. Medicine (Baltimore) 1988 67 132 143 3280944
16. Sepsis and solid organ transplantation. AC Kalil H Dakroub AG Freifeld, Curr Drug Targets 2007 8 533 541 10.2174/138945007780362746 17430124
17. Current concepts and perspectives of immunosuppression in organ transplantation. MN Scherer B Banas K Mantouvalou, et al. Langenbecks Arch Surg 2007 392 511 523 10.1007/s00423-007-0188-z 17450373
18. Delayed introduction of reduced-dose tacrolimus, and renal function in liver transplantation: the 'ReSpECT' study. JM Neuberger RD Mamelok P Neuhaus, et al. Am J Transplant 2009 9 327 336 10.1111/j.1600-6143.2008.02493.x 19120077
19. Optimal two-stage designs for phase II clinical trials. R Simon, Control Clin Trials 1989 10 1 10 10.1016/0197-2456(89)90015-9 2702835